January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
June 2020 in “Annals of the Rheumatic Diseases” Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
May 2019 in “Clinica chimica acta” The study developed methods to measure biomarkers in mice and found differences in hormone levels linked to gut microbiota diversity and stress response.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
14 citations
,
January 2024 in “Skin Research and Technology” The study suggested certain immune cells might cause alopecia areata, but it was retracted.
2 citations
,
May 2022 in “Tropical Journal of Pharmaceutical Research” Probiotics may help improve symptoms in rheumatoid arthritis patients.
4 citations
,
June 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
1 citations
,
April 2013 in “PubMed” September 2019 in “Journal of Investigative Dermatology” IL-17 and certain immune cells are linked to more severe alopecia areata.
45 citations
,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
38 citations
,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
March 2025 in “SKIN The Journal of Cutaneous Medicine”
1 citations
,
February 2021 in “Gastroenterology” A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
March 2025 in “Archives of Dermatological Research” miR-155-5p can help diagnose and track alopecia areata severity.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
49 citations
,
December 2018 in “Journal of Investigational Allergology and Clinical Immunology” Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
February 2024 in “Health Sciences” Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.
August 2024 in “Revista Científica Multidisciplinar Núcleo do Conhecimento” Malassezia restricta may be linked to intestinal diseases like Crohn's and ulcerative colitis.
10 citations
,
January 2021 in “Annals of dermatology/Annals of Dermatology” Nivolumab can cause hair loss as a rare side effect.